Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis

BackgroundRecent evidence has underscored the role of hypoxia and angiogenesis in the pathogenesis of idiopathic fibrotic lung disease. Inhibitor of growth family member 4 (ING4) has recently attracted much attention as a tumor suppressor gene, due to its ability to inhibit cancer cell proliferation, migration and angiogenesis. The aim of our study was to investigate the role of ING4 in the pathogenesis of pulmonary fibrosis both in the bleomycin (BLM)-model and in two different types of human pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and cryptogenic organizing pneumonia (COP).MethodsExperimental model of pulmonary fibrosis was induced by a single tail vein injection of bleomycin in 6- to 8-wk-old C57BL/6mice. Tissue microarrays coupled with qRT-PCR and immunohistochemistry were applied in whole lung samples and paraffin-embedded tissue sections of 30 patients with IPF, 20 with COP and 20 control subjects.ResultsA gradual decline of ING4 expression in both mRNA and protein levels was reported in the BLM-model. ING4 was also found down-regulated in IPF patients compared to COP and control subjects. Immunolocalization analyses revealed increased expression in areas of normal epithelium and in alveolar epithelium surrounding Masson bodies, in COP lung, whereas showed no expression within areas of active fibrosis within IPF and COP lung. In addition, ING4 expression levels were negatively correlated with pulmonary function parameters in IPF patients.ConclusionOur data suggest a potential role for ING4 in lung fibrogenesis. ING4 down-regulation may facilitate aberrant vascular remodelling and fibroblast proliferation and migration leading to progressive disease.

[1]  B. Willis,et al.  TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[2]  N. Siafakas,et al.  Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. , 2005, Chest.

[3]  G. Kollias,et al.  Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis , 2006, PloS one.

[4]  A. Ozer,et al.  Regulation of HIF by Prolyl hydroxylases: Recruitment of the Candidate Tumor Suppressor Protein ING4 , 2005, Cell cycle.

[5]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[6]  N. Kaminski,et al.  Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? , 2008, PLoS medicine.

[7]  L. Woolner,et al.  Pulmonary fibrosis. , 1954, The Medical clinics of North America.

[8]  F. Ishikawa,et al.  Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. , 2007, The Journal of clinical investigation.

[9]  R. D. du Bois.  Mechanisms of scleroderma-induced lung disease. , 2007, Proceedings of the American Thoracic Society.

[10]  A. Nicholson,et al.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. , 2005, The American journal of pathology.

[11]  P. Lansdorp,et al.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis , 2008, Proceedings of the National Academy of Sciences.

[12]  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.

[13]  Yen-Pei Christy Chang,et al.  Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Demosthenes Bouros,et al.  Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander? , 2006, Respiratory research.

[15]  M. Chin,et al.  Biological functions of the ING family tumor suppressors , 2004, Cellular and Molecular Life Sciences CMLS.

[16]  S. Phan.  Fibroblast phenotypes in pulmonary fibrosis. , 2003, American journal of respiratory cell and molecular biology.

[17]  S. Phan,et al.  Regulation of telomerase activity in rat lung fibroblasts. , 2002, American journal of respiratory cell and molecular biology.

[18]  Vassilis Aidinis,et al.  Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. , 2007, American journal of respiratory and critical care medicine.

[19]  R. Mason,et al.  TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT) , 2005, Respiratory research.

[20]  Chao Xing,et al.  Adult-onset pulmonary fibrosis caused by mutations in telomerase , 2007, Proceedings of the National Academy of Sciences.

[21]  Suwon Kim.  HuntING4 New Tumor Suppressors , 2005, Cell cycle.

[22]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[23]  R. Jain,et al.  The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis , 2004, Nature.

[24]  B. Willis,et al.  TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease , 2007 .

[25]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[26]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[27]  Abdullah Ozer,et al.  The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Harris,et al.  Novel Splice Variants of ING4 and Their Possible Roles in the Regulation of Cell Growth and Motility* , 2006, Journal of Biological Chemistry.

[29]  B. Willis,et al.  Epithelial origin of myofibroblasts during fibrosis in the lung. , 2006, Proceedings of the American Thoracic Society.

[30]  S. Colla,et al.  The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. , 2007, Blood.

[31]  C. Marosi,et al.  Diversity of cytogenetic and pathohistologic profiles in glioblastoma. , 2006, Cancer genetics and cytogenetics.

[32]  Y. Ninomiya,et al.  Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. , 2005, Gene.

[33]  K. Chin,et al.  A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Kumamoto,et al.  Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. , 2007, Cancer research.

[35]  M. Martinka,et al.  Role of ING4 in human melanoma cell migration, invasion and patient survival. , 2008, Carcinogenesis.

[36]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[37]  R. Strieter.  Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. , 2005, Chest.

[38]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[39]  N. Siafakas,et al.  Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. , 2006, Chest.

[40]  Demosthenes Bouros,et al.  Current and future therapeutic approaches in idiopathic pulmonary fibrosis , 2005, European Respiratory Journal.

[41]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[42]  B. Uhal,et al.  Epithelial apoptosis in the initiation of lung fibrosis , 2003, European Respiratory Journal.